Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Mercury exposure, risk factors, and perceptions among women of childbearing age in an artisanal gold mining region of the Peruvian Amazon.

Gonzalez DJX, Arain A, Fernandez LE.

Environ Res. 2019 Dec;179(Pt A):108786. doi: 10.1016/j.envres.2019.108786. Epub 2019 Oct 4.

PMID:
31605870
2.

Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.

Junco JA, Rodríguez R, Fuentes F, Baladrón I, Castro MD, Calzada L, Valenzuela C, Bover E, Pimentel E, Basulto R, Arteaga N, Cid-Arregui A, Sariol F, González L, Porres-Fong L, Medina M, Rodríguez A, Garay AH, Reyes O, López M, de Quesada L, Alvarez A, Martínez C, Marrero M, Molero G, Guerra A, Rosales P, Capote C, Acosta S, Vela I, Arzuaga L, Campal A, Ruiz E, Rubio E, Cedeño P, Sánchez MC, Cardoso P, Morán R, Fernández Y, Campos M, Touduri H, Bacardi D, Feria I, Ramirez A, Cosme K, Saura PL, Quintana M, Muzio V, Bringas R, Ayala M, Mendoza M, Fernández LE, Carr A, Herrera L, Guillén G.

Front Oncol. 2019 Feb 25;9:49. doi: 10.3389/fonc.2019.00049. eCollection 2019.

3.

The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes.

Cruz-Leal Y, Grubaugh D, Nogueira CV, Lopetegui-González I, Del Valle A, Escalona F, Laborde RJ, Alvarez C, Fernández LE, Starnbach MN, Higgins DE, Lanio ME.

Front Immunol. 2018 Nov 5;9:2473. doi: 10.3389/fimmu.2018.02473. eCollection 2018.

4.

GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.

Labrada M, Dorvignit D, Hevia G, Rodríguez-Zhurbenko N, Hernández AM, Vázquez AM, Fernández LE.

Semin Oncol. 2018 Jan;45(1-2):41-51. doi: 10.1053/j.seminoncol.2018.04.003. Epub 2018 May 7. Review.

5.

Mercury Contamination in Riverine Sediments and Fish Associated with Artisanal and Small-Scale Gold Mining in Madre de Dios, Peru.

Martinez G, McCord SA, Driscoll CT, Todorova S, Wu S, Araújo JF, Vega CM, Fernandez LE.

Int J Environ Res Public Health. 2018 Jul 26;15(8). pii: E1584. doi: 10.3390/ijerph15081584.

6.

Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.

Valdes-Zayas A, Gonzalez Z, Mulens V, Vega AM, Perez K, Lorenzo-Luaces P, Rubio MC, Estevez A, Curbelo I, Fernandez LE, Crombet T, Mazorra Z.

J Immunother. 2017 Oct;40(8):289-301. doi: 10.1097/CJI.0000000000000175.

PMID:
28604556
7.

Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response.

Laborde RJ, Sanchez-Ferras O, Luzardo MC, Cruz-Leal Y, Fernández A, Mesa C, Oliver L, Canet L, Abreu-Butin L, Nogueira CV, Tejuca M, Pazos F, Álvarez C, Alonso ME, Longo-Maugéri IM, Starnbach MN, Higgins DE, Fernández LE, Lanio ME.

J Immunol. 2017 Apr 1;198(7):2772-2784. doi: 10.4049/jimmunol.1600310. Epub 2017 Mar 3.

8.

Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3/VSSP Vaccine in Advanced Breast Cancer Patients.

de la Torre A, Pérez K, Vega AM, Santiesteban E, Ruiz R, Hernández L, Durrutí D, Viada CE, Sánchez L, Álvarez M, Durán Y, Moreno YG, Arencibia M, Cepeda M, Domecq M, Cabrera L, Sánchez JL, Hernández JJ, Valls AR, Fernández LE.

Breast Cancer (Auckl). 2016 Feb 18;10:5-11. doi: 10.4137/BCBCR.S32785. eCollection 2016.

9.

Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.

Fernández A, Oliver L, Alvarez R, Fernández LE, Lee KP, Mesa C.

Hum Vaccin Immunother. 2014;10(11):3251-60. doi: 10.4161/hv.29847. Review.

10.

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Labrada M, Pablos I, Prete F, Hevia G, Clavell M, Benvenuti F, Fernández LE.

Hum Vaccin Immunother. 2014;10(8):2312-20. doi: 10.4161/hv.29161.

11.

Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells.

Fernández A, Oliver L, Alvarez R, Hernández A, Raymond J, Fernández LE, Mesa C.

J Immunother Cancer. 2014 Mar 11;2:5. doi: 10.1186/2051-1426-2-5. eCollection 2014.

12.

Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma.

Osorio M, Gracia E, Reigosa E, Hernandez J, de la Torre A, Saurez G, Perez K, Viada C, Cepeda M, Carr A, Avila Y, Rodríguez M, Fernandez LE.

Cancer Manag Res. 2012;4:341-5. doi: 10.2147/CMAR.S22617. Epub 2012 Oct 5.

13.

NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial.

de la Torre A, Hernandez J, Ortiz R, Cepeda M, Perez K, Car A, Viada C, Toledo D, Guerra PP, García E, Arboláez M, Fernandez LE.

Breast Cancer (Auckl). 2012;6:151-7. doi: 10.4137/BCBCR.S8488. Epub 2012 Sep 24.

14.

Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions.

Oliver L, Fernández A, Raymond J, López-Requena A, Fernández LE, Mesa C.

Vaccine. 2012 Apr 19;30(19):2963-72. doi: 10.1016/j.vaccine.2012.02.054. Epub 2012 Mar 3.

PMID:
22391399
15.

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.

Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R.

Cancer Biol Ther. 2011 Feb 15;11(4):373-82. Epub 2011 Feb 15.

PMID:
21150278
16.

Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.

Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE, Bronte V.

J Immunol. 2011 Jan 1;186(1):264-74. doi: 10.4049/jimmunol.1001465. Epub 2010 Dec 6.

17.

NGcGM3 ganglioside: a privileged target for cancer vaccines.

Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF.

Clin Dev Immunol. 2010;2010:814397. doi: 10.1155/2010/814397. Epub 2010 Oct 27. Review.

18.

Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.

Labrada M, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, Veloso RC, Vérez V, Fernández LE.

Expert Opin Biol Ther. 2010 Feb;10(2):153-62. doi: 10.1517/14712590903443084.

PMID:
20088712
19.

Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.

Mazorra Z, Mesa C, Fernández A, Fernández LE.

Cancer Immunol Immunother. 2008 Dec;57(12):1771-80. doi: 10.1007/s00262-008-0503-8. Epub 2008 Mar 20.

PMID:
18351335
20.

Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function.

de León J, Fernández A, Clavell M, Labrada M, Bebelagua Y, Mesa C, Fernández LE.

Int Immunol. 2008 Apr;20(4):591-600. doi: 10.1093/intimm/dxn018. Epub 2008 Feb 29.

PMID:
18310617

Supplemental Content

Loading ...
Support Center